Cantor Fitzgerald Starts SCYNEXIS (SCYX) at Overweight

January 5, 2021 4:04 PM EST
Get Alerts SCYX Hot Sheet
Price: $6.91 +0.58%

Rating Summary:
    15 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 13 | New: 31
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Cantor Fitzgerald analyst Louise Chen initiates coverage on SCYNEXIS (NASDAQ: SCYX) with a Overweight rating and a price target of $30.00.

The analyst comments "The peak sales potential of ibrexafungerp, for the treatment of fungal infections, is underappreciated, in our view. Therefore, we expect upwards earnings revisions to drive SCYX shares higher. Upwards earnings revisions could come from: 1) The approval of ibrexafungerp for vulvovaginal candidiasis (VVC) on or before its PDUFA date of 6/1/21; 2) Positive, phase 3 data from SCYX's CANDLE study for the prevention of recurrent VVC in 2H21, 3) Positive data readout for Phase 2 SCYNERGIA invasive aspergillosis study in 2H21, and 4) Positive data readouts for refractory invasive fungal infections (FURI) and candida auris (CARES) in 1Q21. We also think SCYX is an interesting company in a consolidating space."

For an analyst ratings summary and ratings history on SCYNEXIS click here. For more ratings news on SCYNEXIS click here.

Shares of SCYNEXIS closed at $7.17 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Cantor Fitzgerald, Earnings, Louise Chen, PDUFA